Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1502279 | 0.74 | IDO1 (0.45) | NAMPT | |
| SCHEMBL17208821 | 0.72 | ATR (0.51) | CYP17A1NAMPTATRMEN1KMT2A | |
| SCHEMBL27345606 | 0.72 | ATR (0.42) | CYP17A1NAMPTATR | |
| SCHEMBL25944367 | 0.71 | ATR (0.40) | CYP17A1NAMPTATRMEN1KMT2A | |
| SCHEMBL1566862 | 0.71 | RAB9A (0.52) | CYP17A1NAMPTATRMEN1KMT2A | |
| Pyridine SCHEMBL28155747 | 0.71 | RAB9A (0.46) | CYP17A1NAMPTATRMEN1KMT2A | |
| SCHEMBL19180758 | 0.70 | NAMPT (0.54) | CYP17A1NAMPTATRRAB9A | |
| SCHEMBL14428036 | 0.70 | NAMPT (0.54) | CYP17A1NAMPTATRRAB9A | |
| SCHEMBL31363541 | 0.70 | LCK (0.47) | CYP17A1NAMPTATR | |
| SCHEMBL1829342 | 0.70 | TP53 (0.42) | HRH3MEN1KMT2ARAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| CN-116194439-A | SOCE inhibitors and therapeutic uses thereof | 国家医疗保健研究所 | 2023-05-30 | — | — | CN | disclosed |
| CN-108570048-A | Substituted heteroaryl compound and combinations thereof and purposes | 广东东阳光药业有限公司 | 2018-09-25 | — | — | CN | disclosed |
| US-8552022-B2 | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120142706-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME LLC | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142706-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR27, GCGR | CYP17A1 875/4885NAMPT 2670/4885ATR 4384/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | CYP17A1 2426/4885NAMPT 4202/4885ATR 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.